FDA rule would allow generic drugmakers to update labels
The Food and Drug Administration (FDA) plans to issue a new rule that will allow generic drugmakers to make changes to their drugs labeling.
July 05, 2013 at 05:00 AM
4 minute read
The original version of this story was published on Law.com
The Food and Drug Administration (FDA) plans to issue a new rule that will allow generic drugmakers to make changes to their drugs' labeling.
Federal law dictates that generic drug labels must be identical to their brand-name counterparts' labels. Currently, generic manufacturers aren't allowed to update their drug labels even if they learn of a potential safety issue that isn't included on the existing label.
The FDA's new rule, which the agency plans to issue by September, would make generic and brand-name drug companies equally responsible for drug safety. An FDA spokeswoman told the Wall Street Journal that it was too early to know precisely how the agency would word the new rule.
The rule could vastly alter the drug litigation landscape. Generic manufacturers are currently shielded from liability when their drugs cause harm to patients. In the 2011 case Pliva v. Mensing, the Supreme Court ruled that federal labeling laws preempted plaintiffs' liability suits against generic drugmakers.
Sen. Patrick Leahy, D-Vt., praised the proposed rule. “A consumer should not have her rights foreclosed simply because she takes the generic version of a prescription drug,” he told the Journal. “I welcome this first step by the Food and Drug Administration to address this troubling inconsistency in the law.”
For more information, read the New York Times and Reuters.
For more InsideCounsel stories about pharmaceuticals, read:
The Food and Drug Administration (FDA) plans to issue a new rule that will allow generic drugmakers to make changes to their drugs' labeling.
Federal law dictates that generic drug labels must be identical to their brand-name counterparts' labels. Currently, generic manufacturers aren't allowed to update their drug labels even if they learn of a potential safety issue that isn't included on the existing label.
The FDA's new rule, which the agency plans to issue by September, would make generic and brand-name drug companies equally responsible for drug safety. An FDA spokeswoman told the Wall Street Journal that it was too early to know precisely how the agency would word the new rule.
The rule could vastly alter the drug litigation landscape. Generic manufacturers are currently shielded from liability when their drugs cause harm to patients. In the 2011 case Pliva v. Mensing, the Supreme Court ruled that federal labeling laws preempted plaintiffs' liability suits against generic drugmakers.
Sen. Patrick Leahy, D-Vt., praised the proposed rule. “A consumer should not have her rights foreclosed simply because she takes the generic version of a prescription drug,” he told the Journal. “I welcome this first step by the Food and Drug Administration to address this troubling inconsistency in the law.”
For more information, read the
For more InsideCounsel stories about pharmaceuticals, read:
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
NOT FOR REPRINT
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
You Might Like
View AllWhy Seemingly Simple Off-Channel Communication Rules Still Vex Finance Industry
5 minute readTrending Stories
- 1The Law Firm Disrupted: Playing the Talent Game to Win
- 2Preparing Your Law Firm for 2025: Smart Ways to Embrace AI & Other Technologies
- 3BD Settles Thousands of Bard Hernia Mesh Lawsuits
- 4GlaxoSmithKline Settles Most Zantac Lawsuits for $2.2B
- 5A&O Shearman Adopts 3-Level Lockstep Pay Model Amid Shift to All-Equity Partnership
Featured Firms
Law Offices of Gary Martin Hays & Associates, P.C.
(470) 294-1674
Law Offices of Mark E. Salomone
(857) 444-6468
Smith & Hassler
(713) 739-1250